Synairgen is a developer of respiratory drugs. The main project uses inhaled interferon beta for the treatment of viral infection in asthma and chronic obstructive pulmonary disease (COPD). Synairgen floated in October 2004, when it raised 10m - 9m net of expenses - at 130p a share. That valued the company at 28.2m. Synairgen raised 6.35m at 17p a share in June 2009. (

Sector: Health

News blog

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds